UNICYCIVE THERAPEUTICS, INC.
Income Statement
| Line Item | Aug 2026 | Jun 2026 | May 2026 | Mar 2026 | Mar 2026 | Dec 2025 | Nov 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $2.8M | — | $1.6M | — | — | — | $3.0M |
| SG&A Expense | — | $7.4M | — | $6.8M | — | — | — | $4.4M |
| Operating Income | — | $-10.1M | — | $-8.4M | — | — | — | $-7.3M |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | — | $-1.7M | — | $-12.8M | — | — | — | $-6.0M |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | — | $-0.06 | — | $-0.54 | — | — | — | $-0.17 |
| EPS (Diluted) | — | $-0.06 | — | $-0.54 | — | — | — | $-0.17 |
| Shares Outstanding (Basic) | 27.9M | 26.9M | 26.7M | 23.9M | 25.2M | 22.1M | 43.0M | 36.1M |
| Shares Outstanding (Diluted) | 27.9M | 26.9M | 26.7M | 23.9M | 25.2M | 22.1M | 43.0M | 36.1M |
| Dividends Per Share | — | — | — | — | — | — | — | — |